# Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01

> **NCT07290894** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute, Naples** · enrollment: 80 (estimated)

## Conditions studied

- Vulva Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Lenvatinib Capsules

## Key facts

- **NCT ID:** NCT07290894
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-12
- **Primary completion:** 2031-10
- **Final completion:** 2031-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07290894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07290894, "Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07290894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*